Atrasentan

Atrasentan is an experimental drug that is being studied for the treatment of various types of cancer, including non-small cell lung cancer.

It is an endothelin receptor antagonist selective for subtype A (ETA). While other drugs of this type (sitaxentan, ambrisentan) exploit the vasoconstrictive properties of endothelin and are mainly used for the treatment of pulmonary arterial hypertension, atrasentan blocks endothelin induced cell proliferation.